X4 Pharmaceuticals Inc expected to post a loss of $4.44 a share - Earnings Preview

X4 Pharmaceuticals

29/04/2025 14:16

X4 Pharmaceuticals Inc XFOR.OQ XFOR.O is expected to show a rise in quarterly revenue when it reports  results on May 1 for the period ending March 31 2025

The Boston Massachusetts-based  company is expected to report revenue of $1.999 million, according to the mean estimate from 4 analysts, based on LSEG data.

‚ÄãLSEG's mean analyst estimate for X4 Pharmaceuticals Inc is for a loss of $4.44 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äã

Wall Street's median 12-month price target for X4 Pharmaceuticals Inc is $67.50‚Äã, above‚Äã its last closing price of $5.34. ‚Äã‚Äã‚Äã

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äã

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-5.40
-5.25
-6.00
Missed
-14.3
Sep. 30 2024
-4.50
-5.19
-5.40
Missed
-4.1
Jun. 30 2024
3.80
0.17
-2.10
Missed
-1,325.9‚Äã
Mar. 31 2024
-4.65
-4.89
-7.80
Missed
-59.6
‚Äã‚ÄãDec. 31 2023
-5.10
-4.59
-3.00
Beat
34.6
Sep. 30 2023
-4.61
-4.47
-0.30
Beat
93.3‚Äã
Jun. 30 2023
-4.86
-4.90
-9.90
Missed
-102
Mar. 31 2023
-6.35
-6.51
-4.80
Beat
26.3

This summary was machine generated April 29 at 13:16 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)